BRIP1 mutation
|
Prostate Cancer
|
BRIP1 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
BRIP1 mutation
|
Ovarian Cancer
|
BRIP1 mutation
|
Ovarian Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
BRIP1 mutation
|
Prostate Cancer
|
BRIP1 mutation
|
Prostate Cancer
|
rucaparib Sensitive: C2 – Inclusion Criteria
|
rucaparib Sensitive: C2 – Inclusion Criteria
|
BRIP1 mutation
|
Urothelial Cancer
|
BRIP1 mutation
|
Urothelial Cancer
|
olaparib Sensitive: C2 – Inclusion Criteria
|
olaparib Sensitive: C2 – Inclusion Criteria
|
BRIP1 mutation
|
HER2 Negative Breast Cancer
|
BRIP1 mutation
|
HER2 Negative Breast Cancer
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
BRIP1 mutation
|
Pancreatic Cancer
|
BRIP1 mutation
|
Pancreatic Cancer
|
nivolumab + ABT-888 Sensitive: C3 – Early Trials
|
nivolumab + ABT-888 Sensitive: C3 – Early Trials
|
BRIP1 mutation
|
Colon Cancer
|
BRIP1 mutation
|
Colon Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|